HOUSE_OVERSIGHT_028417.jpg

3.31 MB
View Original

Extraction Summary

2
People
5
Organizations
2
Locations
5
Events
3
Relationships
4
Quotes

Document Information

Type: Data extract from a news article, identified as exhibit 'house oversight 028417'.
File Size: 3.31 MB
Summary

This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.

People (2)

Name Role Context
Mr. Hugin Executive at Celgene, Political Candidate
Mentioned as arriving at Celgene in June 1999. Also mentioned as a political candidate in New Jersey facing difficult...
Mr. Menendez Political Candidate
Mentioned as a political opponent of Mr. Hugin in a New Jersey race. Noted to have vulnerabilities, but benefits from...

Organizations (5)

Name Type Context
Celgene
A pharmaceutical company in New Jersey that marketed the drug Thalomid (thalidomide). Mr. Hugin arrived there in June...
F.D.A. (Food and Drug Administration)
The U.S. regulatory body that approved Celgene's application for thalidomide in 1998 and mandated a strict distributi...
Democrats
Political party mentioned as having nearly 900,000 more registered voters than Republicans in New Jersey.
Republicans
Political party mentioned in the context of New Jersey voter registration numbers.
HOUSE_OVERSIGHT
Appears in the footer of the document ('HOUSE_OVERSIGHT_028417'), suggesting this document is an exhibit for a congre...

Timeline (5 events)

1960s
The drug thalidomide became notorious after being traced to thousands of birth defects worldwide.
Worldwide
1990s
Thalidomide, previously obscure, saw a resurgence in interest. AIDS activists were smuggling it into the U.S. and selling it via 'buyers clubs' for AIDS-related conditions.
United States
AIDS activists
1998
Celgene's application was approved by the F.D.A. to treat erythema nodosum leprosum, a complication of leprosy.
United States
Celgene F.D.A.
2007
Celgene reported that only about 100 prescriptions per year were written for the approved skin condition (leprosy complication).
United States
June 1999
Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalomid.
New Jersey

Locations (2)

Location Context
The location of Celgene and the political race between Mr. Hugin and Mr. Menendez.
Location where leprosy is extremely rare and where the F.D.A. regulates drugs.

Relationships (3)

Mr. Hugin Employee/Executive Celgene
Text states 'When Mr. Hugin arrived at Celgene in June 1999...'
Mr. Hugin Political Opponents Mr. Menendez
Text describes a political race in New Jersey between the two.
Celgene Regulated Entity / Regulator F.D.A.
Text describes Celgene getting drug approval from the F.D.A. and being required to follow its distribution rules.

Key Quotes (4)

"When Mr. Hugin arrived at Celgene in June 1999, the company was struggling to figure out how to turn a profit on its only marketed drug, Thalomid, which had been approved a year earlier to treat a rare skin condition caused by leprosy."
Source
HOUSE_OVERSIGHT_028417.jpg
Quote #1
"Thalomid was Celgene’s brand name for thalidomide, an old drug that became notorious in the 1960s after it was traced to thousands of birth defects worldwide."
Source
HOUSE_OVERSIGHT_028417.jpg
Quote #2
"F.D.A. officials, alarmed that a notorious drug was being sold illicitly, took the unusual step of seeking out drug companies that might be willing to bring thalidomide to market legally."
Source
HOUSE_OVERSIGHT_028417.jpg
Quote #3
"But leprosy was hardly the point: The F.D.A.’s main goal was to keep the drug from harming infants, and it did so by requiring that Celgene set up a first-of-its-kind distribution system that would limit prescriptions to preapproved doctors and pharmacies."
Source
HOUSE_OVERSIGHT_028417.jpg
Quote #4

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document